Compare AKBA & MITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | MITT |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 245.5M |
| IPO Year | 2014 | 2011 |
| Metric | AKBA | MITT |
|---|---|---|
| Price | $0.59 | $5.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.92 | ★ $8.58 |
| AVG Volume (30 Days) | ★ 6.4M | 409.8K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 18.05% |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.69 |
| P/E Ratio | ★ N/A | $532.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $5.20 |
| 52 Week High | $3.19 | $9.27 |
| Indicator | AKBA | MITT |
|---|---|---|
| Relative Strength Index (RSI) | 20.35 | 33.22 |
| Support Level | N/A | N/A |
| Resistance Level | $0.98 | $8.00 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 4.44 | 17.12 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.